- The USPTO issues patent No. 8,771,701 entitled "Compositions for immunotherapy and uses thereof" protecting Prima BioMed's (PBMD +9.8%) CVac technology. CVac is a personalized immunotherapy. The patent's term extends to August 2022.
- The patent covers the method of composition and the method of use of CVac, which uses the patient's own dendritic cells that are reinjected back into the patient to generate a cytotoxic T cell response against the mucin 1 antigen.